Loading
CT
Cascadian Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Myers Scott Dunseth, was filed 14 Aug 2017.
Cascadian Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Cascadian Therapeutics, Inc. as filed with SEC (Form 4). Nothing new has been filed by managers of Cascadian Therapeutics, Inc. in twelve months, the latest record being from 13 March 2018.
Since 2016, the database holds 10 purchases and no sales by insiders of the company.
Elsewhere in the same market, our signals recently picked up insider purchases at GameStop Corp. and Heico Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
78
Thresholds
n/a
Buy Volume
€396,299
10 ops. · all time
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2011FY ended December 2011 · cache
Income statement
Revenue129.3k
Net income-50.8M-39264.8% margin
Last declaration on 13 March 2018
Declarations78 total
10,882,574 sharesCommon StockSEC:0001209191-18-019367:0
10,882,574 sharesCommon StockSEC:0001209191-18-019369:0
10,125 sharesCommon StockSEC:0000899243-18-007306:0
10,882,574 sharesCommon StockSEC:0001209191-18-019379:0
60,185 sharesCommon StockSEC:0000899243-18-007293:0
10,882,574 sharesCommon StockSEC:0001209191-18-019375:0
6,515 sharesCommon StockSEC:0000899243-18-007294:0
13,677 sharesCommon StockSEC:0000899243-18-007308:0
10,882,574 sharesCommon StockSEC:0001209191-18-019376:0
10,882,574 sharesCommon StockSEC:0001209191-18-019372:0
3,639 sharesCommon StockSEC:0000899243-18-007303:0
37,394 sharesCommon StockSEC:0000899243-18-007307:0
21,006 sharesCommon StockSEC:0000899243-18-007301:0
10,882,574 sharesCommon StockSEC:0001209191-18-019374:0
10,882,574 sharesCommon StockSEC:0001209191-18-019368:0
10,882,574 sharesCommon StockSEC:0001209191-18-019378:0
10,882,574 sharesCommon StockSEC:0001209191-18-019371:0
5,237 sharesCommon StockSEC:0000899243-18-007292:0
10,315 sharesCommon StockSEC:0000899243-18-007310:0
56,787 sharesCommon StockSEC:0000899243-18-007300:0
1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012470:0
1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012477:0
1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012481:0
1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012474:0
1,818,000 shares@ US$3.30100.0% of flowCommon StockSEC:0001209191-18-012472:0
25 of 78 declarations
About Cascadian Therapeutics, Inc.
Cascadian Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for cancer. It specializes in targeted therapies and innovative approaches to improve patient outcomes.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
